Jun 2026 (Q2 FY26) — Aug 3, 2026
Stoke Therapeutics Q2 FY26 — EMPEROR Study Progress and Strong Financial Position
Read the full callStoke Therapeutics (STOK) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Stoke Therapeutics earnings: last reported Mon, 3 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 9.3 | −32.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -701.6 | −504.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -61.6 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$24.82 +2.69% · +$0.65
Performance −26.0% 1Y
1Y: $33.53 on 17 Oct 2025 → $24.82. High $38.35 (10 Mar 2026), low $22.37 (10 Nov 2025).
- Previous close
- $24.17
- 52-week range
- $22.37 – $38.35
- One year
- −28.37%
Overview
- Symbol
- STOK
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Stoke Therapeutics earnings calls (STOK)
Financials
What the filings say
Net profit, year on year: −162% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 5 | 23 | 159 | 14 | 11 | 1 | 6 | 9 |
| Operating profit | -30 | -14 | 111 | -27 | -43 | -61 | -53 | -65 |
| Operating margin | −613.1% | −60.4% | 70.2% | −197.6% | −405.3% | −4382.2% | −857.6% | −701.6% |
| Other income | 4 | 3 | 3 | 4 | 3 | 4 | 3 | 4 |
| Interest | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -26 | — | 114 | -23 | -40 | — | -50 | -62 |
| Tax rate | 0.0% | — | 1.1% | 0.0% | 3.2% | — | 0.0% | 0.0% |
| Net profit | -26 | -10 | 113 | -23 | -38 | -58 | -50 | -62 |
| EPS ($ per share) | -0.47 | — | 1.95 | -0.40 | -0.65 | — | -0.79 | -0.93 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -26 | -58 | -110 | -196 | -297 | -402 | -491 | -498 |
| Total liabilities | 2 | 4 | 12 | 21 | 71 | 69 | 43 | 66 |
| Fixed assets | 1 | 3 | 3 | 4 | 7 | 6 | 4 | 3 |
| Total assets | 108 | 229 | 298 | 239 | 256 | 228 | 272 | 418 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -11 | -31 | -42 | -67 | -32 | -81 | -87 | 46 |
| Cash from investing | -1 | -2 | -1 | -76 | -46 | 106 | -107 | -187 |
| Cash from financing | 116 | 150 | 108 | 1 | 46 | 53 | 131 | 97 |
| Net cash flow | 104 | 117 | 65 | -142 | -31 | 78 | -63 | -44 |
| Capital expenditure | -1 | -2 | -1 | -1 | -4 | -2 | -0 | -1 |
| Free cash flow | -12 | -33 | -43 | -68 | -36 | -83 | -87 | 45 |
Insider filings
104 filings between Nov 3, 2025 and Oct 2, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$8.94M
83 sales by 8 insiders
60% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 21
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Krainer Adrian R. | — | $3.90M | Mar 10, 2026 |
| Ticho Barry | — | $1.88M | Oct 1, 2026 |
| Kaye Edward M. MD | — | $1.37M | Aug 18, 2026 |
| Allan Jonathan | — | $1.32M | Oct 2, 2026 |
| TZIANABOS ARTHUR | — | $174.2K | Mar 10, 2026 |
| Leggett Thomas | — | $147.1K | Mar 18, 2026 |
| Hoitt Jason | — | $119.3K | Mar 18, 2026 |
| LEVIN ARTHUR A | — | $22.3K | Mar 13, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 2, 2026 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Sale 10b5-1 plan | 627 | $16.5K |
| Oct 1, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 1,051 | $27.5K |
| Sep 1, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 1,600 | $49.7K |
| Sep 1, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 3,945 | $120.4K |
| Aug 18, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale | 4,525 | $144.8K |
| Aug 18, 2026 | Kaye Edward M. MD Director | Sale | 11,930 | $381.8K |
| Aug 18, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale | 242 | $7.9K |
| Aug 18, 2026 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Sale | 145 | $4.7K |
| Aug 18, 2026 | Kaye Edward M. MD Director | Sale | 637 | $20.7K |
| Aug 18, 2026 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Sale | 2,716 | $86.9K |
| Aug 14, 2026 | Kaye Edward M. MD Director | Option exercise | 26,250 | $0 |
| Aug 14, 2026 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Option exercise | 6,000 | $0 |
| Aug 14, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Option exercise | 10,000 | $0 |
| Aug 3, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 5,907 | $171.0K |
| Aug 3, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 1,269 | $37.4K |
| Jul 1, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 6,728 | $219.4K |
| Jul 1, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 500 | $16.6K |
| Jun 16, 2026 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Sale 10b5-1 plan | 1,457 | $43.6K |
| Jun 1, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 1,795 | $54.9K |
| May 1, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 2,243 | $73.5K |
| Apr 1, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 1,838 | $60.0K |
| Mar 20, 2026 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Sale 10b5-1 plan | 8,692 | $292.4K |
| Mar 20, 2026 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Sale 10b5-1 plan | 601 | $20.7K |
| Mar 19, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 1,461 | $43.8K |
| Mar 19, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Option exercise 10b5-1 plan | 1,365 | $3.0K |
| Mar 18, 2026 | Leggett Thomas Chief Financial Officer | Sale | 172 | $5.5K |
| Mar 18, 2026 | Leggett Thomas Chief Financial Officer | Sale | 2,173 | $68.0K |
| Mar 18, 2026 | Hoitt Jason Chief Patient Officer | Sale | 30 | $986 |
| Mar 18, 2026 | Hoitt Jason Chief Patient Officer | Sale | 139 | $4.4K |
| Mar 18, 2026 | Hoitt Jason Chief Patient Officer | Sale | 1,762 | $55.1K |
| Mar 18, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 103 | $3.4K |
| Mar 18, 2026 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Sale | 72 | $2.4K |
| Mar 18, 2026 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Sale | 334 | $10.6K |
| Mar 18, 2026 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Sale | 4,222 | $132.1K |
| Mar 18, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 6,100 | $190.8K |
| Mar 18, 2026 | Leggett Thomas Chief Financial Officer | Sale | 37 | $1.2K |
| Mar 18, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 483 | $15.4K |
| Mar 17, 2026 | Leggett Thomas Chief Financial Officer | Sale | 922 | $30.8K |
| Mar 17, 2026 | Leggett Thomas Chief Financial Officer | Sale | 1,274 | $41.7K |
| Mar 17, 2026 | Hoitt Jason Chief Patient Officer | Sale | 748 | $25.0K |
| Mar 17, 2026 | Hoitt Jason Chief Patient Officer | Sale | 1,033 | $33.8K |
| Mar 17, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 3,577 | $117.1K |
| Mar 17, 2026 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Sale | 1,791 | $59.8K |
| Mar 17, 2026 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Sale | 2,476 | $81.1K |
| Mar 17, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 2,587 | $86.3K |
| Mar 15, 2026 | Allan Jonathan GENERAL COUNSEL & CORP SEC | Option exercise | 7,475 | $0 |
| Mar 15, 2026 | Ticho Barry CHIEF MEDICAL OFFICER | Option exercise | 13,100 | $0 |
| Mar 15, 2026 | Kaye Edward M. MD Director | Option exercise | 35,500 | $0 |
| Mar 15, 2026 | Leggett Thomas Chief Financial Officer | Option exercise | 14,750 | $0 |
| Mar 15, 2026 | Hoitt Jason Chief Patient Officer | Option exercise | 10,000 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Stoke Therapeutics, Inc.
Free account. Everything above stays public.
Write why you follow Stoke Therapeutics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading